Hexa Healthcare Pvt.ltd., Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Hexa Healthcare Pvt.ltd., Pharmaceutical Export Portfolio Dataset — 2 Products, $3.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hexa Healthcare Pvt.ltd., — Pharmaceutical Exporter Profile (2026) | 2 Products, $3.5K Trade | TransData Nexus

Hexa Healthcare Pvt.ltd.,

Indian Pharmaceutical Exporter · Advanced Diabetes Medications Specialist · $3.5K Total Trade · DGFT Verified

Hexa Healthcare Pvt.ltd., is an Indian pharmaceutical exporter with a total trade value of $3.5K across 2 products in 1 therapeutic categories. Based on 16 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Canagliflozin ($2.4K), Saxagliptin ($1.1K), .

Hexa Healthcare Pvt.ltd., — Export Portfolio & Destination Treemap

Hexa Healthcare Pvt.ltd., pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Hexa Healthcare Pvt.ltd.,? — Company Overview & Market Position

Hexa Healthcare Pvt. Ltd. is a privately held pharmaceutical company based in Mumbai, Maharashtra, India. Established on May 24, 2005, the company is registered under the Corporate Identification Number (CIN) U24230MH2005PTC153478. Hexa Healthcare specializes in the manufacture and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's authorized capital is ₹5 million, with a paid-up capital of ₹3.2 million. As of the latest available data, Hexa Healthcare employs between 51 to 100 individuals. The company's registered office is located at 194 Dattaram Lad Marg, Kalachowki, Mumbai, Maharashtra, India.

What Does Hexa Healthcare Pvt.ltd., Export? — Product Portfolio Analysis

Top Products by Export Value

1Canagliflozin$2.4K 2Saxagliptin$1.1K

Hexa Healthcare Pvt.ltd., Therapeutic Categories — 1 Specializations

Product Portfolio — Top 2 by Export Value

Hexa Healthcare Pvt.ltd., exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Canagliflozin	Advanced Diabetes Medications	$2.4K	8	0.3%	13
2	Saxagliptin	Advanced Diabetes Medications	$1.1K	8	0.0%	11

Hexa Healthcare Pvt.ltd., exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $3.5K. The top category is Advanced Diabetes Medications (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Hexa Healthcare Pvt.ltd., — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Hexa Healthcare Pvt. Ltd. operates manufacturing facilities in Mumbai, Maharashtra, India. While specific details regarding plant locations, capacities, and specializations are not publicly disclosed, the company is known for producing a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products are distributed both domestically and internationally, catering to various therapeutic categories.

3Key Leadership

The leadership team at Hexa Healthcare Pvt. Ltd. includes:

Niren Mansukhlal Shah: Director

Piyush Bharat Shah: Additional Director

These individuals are responsible for overseeing the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Hexa Healthcare Pvt.ltd., Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Hexa Healthcare Pvt. Ltd. has engaged in exporting pharmaceutical products to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export activities are primarily focused on finished pharmaceutical formulations, such as tablets and capsules. Specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly available. However, the company's export data indicates a total export value of $3,000 USD across 16 shipments, with products spanning one therapeutic category. The top two exported products are Canagliflozin and Saxagliptin, with export values of $2,000 and $1,000 USD, respectively. These products are ranked #13 and #11 in their respective categories, holding market shares of 0.3% and 0.0%. The portfolio concentration is high, with the top five products accounting for 100% of the export value.

2Emerging Markets

Hexa Healthcare Pvt. Ltd. has explored opportunities in emerging markets, including regions in Africa, Latin America, and Southeast Asia. While specific details regarding market penetration and WHO prequalification status are not publicly disclosed, the company's export activities suggest an interest in expanding its global footprint. The focus on finished pharmaceutical formulations positions Hexa Healthcare to potentially meet the needs of these markets, where access to quality medicines is a growing priority.

Hexa Healthcare Pvt.ltd., — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Hexa Healthcare Pvt. Ltd.'s FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data indicates a total export value of $3,000 USD across 16 shipments, with products spanning one therapeutic category. The top two exported products are Canagliflozin and Saxagliptin, with export values of $2,000 and $1,000 USD, respectively. These products are ranked #13 and #11 in their respective categories, holding market shares of 0.3% and 0.0%. The portfolio concentration is high, with the top five products accounting for 100% of the export value. Given the limited available information, a comprehensive assessment of the company's FDA status cannot be conducted.

2WHO & EU GMP

Specific information regarding Hexa Healthcare Pvt. Ltd.'s WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's export data indicates a total export value of $3,000 USD across 16 shipments, with products spanning one therapeutic category. The top two exported products are Canagliflozin and Saxagliptin, with export values of $2,000 and $1,000 USD, respectively. These products are ranked #13 and #11 in their respective categories, holding market shares of 0.3% and 0.0%. The portfolio concentration is high, with the top five products accounting for 100% of the export value. Due to the lack of publicly available information, a detailed evaluation of the company's compliance with WHO and EU GMP standards cannot be performed.

Hexa Healthcare Pvt.ltd., — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Hexa Healthcare Pvt. Ltd. operates in the competitive landscape of the pharmaceutical industry, focusing on finished pharmaceutical formulations, particularly in the diabetes medication sector. The company's export data indicates a total export value of $3,000 USD across 16 shipments, with products spanning one therapeutic category. The top two exported products are Canagliflozin and Saxagliptin, with export values of $2,000 and $1,000 USD, respectively. These products are ranked #13 and #11 in their respective categories, holding market shares of 0.3% and 0.0%. The portfolio concentration is high, with the top five products accounting for 100% of the export value. While specific competitors are not identified, the company's focus on a niche market segment suggests a strategic positioning to leverage specialized expertise and potentially differentiate itself in the market.

2Key Differentiators

Hexa Healthcare Pvt. Ltd. differentiates itself through its specialized focus on Advanced Diabetes Medications, offering finished pharmaceutical formulations such as tablets and capsules. The company's export data indicates a total export value of $3,000 USD across 16 shipments, with products spanning one therapeutic category. The top two exported products are Canagliflozin and Saxagliptin, with export values of $2,000 and $1,000 USD, respectively. These products are ranked #13 and #11 in their respective categories, holding market shares of 0.3% and 0.0%. The portfolio concentration is high, with the top five products accounting for 100% of the export value. This strategic focus allows Hexa Healthcare to develop deep expertise in a specific therapeutic area, potentially leading to enhanced product quality and brand recognition among healthcare professionals and patients.

Frequently Asked Questions — Hexa Healthcare Pvt.ltd.,

How many pharmaceutical products does Hexa Healthcare Pvt.ltd., export from India?

Hexa Healthcare Pvt.ltd., exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Canagliflozin ($2.4K), Saxagliptin ($1.1K). Total export value is $3.5K.

What is Hexa Healthcare Pvt.ltd.,'s total pharmaceutical export value?

Hexa Healthcare Pvt.ltd.,'s total pharmaceutical export value is $3.5K, based on 16 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Hexa Healthcare Pvt.ltd., cover?

Hexa Healthcare Pvt.ltd., exports across 1 therapeutic categories. The largest are Advanced Diabetes Medications (100.0%, 2 products).

Get Full Hexa Healthcare Pvt.ltd., Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.